Carol Ann Wallace, MD

Carol Ann Wallace, MD


On staff since July 1979

Children's Title: Division Chief

Academic Title: Professor Emeritus

Research Center: Center for Clinical and Translational Research

"The diseases we treat are rare, so I’m always learning from my patients and my peers. I come to work each day, knowing I will have opportunities to interact with a fabulous team committed to helping our patients realize their potential. In my research to find the best treatment for childhood arthritis, I get to collaborate with an expansive network of colleagues —nationally and internationally — who are working toward the same goals. I just wish there were more pediatric rheumatologists to fulfill the need for the specialized care we provide."

  • Carol A. Wallace, MD, Professor Pediatrics, University of Washington School of Medicine and Seattle Children's Hospital. Dr. Wallace received her MD from the University of Michigan in 1973. She completed both her residency in pediatrics and fellowship in pediatric rheumatology at the University of Washington.

    Following this she was in private practice pediatrics and rheumatology until she joined the University of Washington and Children's Hospital and Regional Medical Center in 1984.   Dr. Wallace’s main focus has been the aggressive treatment of Juvenile Idiopathic Arthritis (JIA) and other Pediatric Rheumatic Diseases.  She has published many of the sentinel studies of the use of methotrexate in the treatment of JIA. Dr. Wallace is the Principal Investigator for an NIH funded clinical trial: Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis. She is also the co-principal investigator for a National Collaborative Study of Autologous Stem-Cell Transplantation for Severe Pediatric Rheumatologic Diseases, and participates in many multicenter clinical trials of new agents for the treatment of JIA.  With remission of disease as the goal of treatment, Dr. Wallace led an effort to develop and validate an international consensus definition for remission of JIA. Dr. Wallace has served on the Pediatric Rheumatology Sub-board for the American Board of Pediatrics, sub-committees of the American College of Rheumatology, has been on the Advisory Committee of the Pediatric Rheumatology Collaborative Study Group and is the immediate past-Chair of the Childhood Arthritis and Rheumatology Research Alliance.

    • Ashley Mercer Island, Washington 02.09.16

      When I was two years old I was diagnosed with JRA, and at five years old I had to get reconstructive surgery on my ankle because it was so severely deformed. I was told that I could never play a sport but I ended up playing club soccer for 18 years thanks to Dr. Wallace. After being told by every doctor that I would never be active, she worked with me for 18 straight years to make sure that I could be. She actually cared about me as her patient, and I haven't found that with any other doctor. She deserves the highest recommendation because of her dedication to every single one of her patients.

    • Lacey Kennewick Washington 04.09.14

      After YEARS of trying to get my son diagnosed, I was sent to Seattle Children Hospital. Within a few minutes Dr Wallace had him diagnosed and had a game plan for treatment. She is professional, through and incredibly intelligent. I couldn't give her a higher recommendation!

    • Sarah Issaquah, WA 08.07.12

      I grew up at Children's due to JRA, and I dreaded the day that I turned eighteen because it meant Dr. Wallace would no longer be my rheumatologist. I can’t recommend her highly enough!

    • Diane Auburn, WA 08.06.12

      After searching for a year for a doctor that could correctly diagnose my daughter's symptoms, Dr. Wallace was able to simply look at my 11-year old daugter and diagnose scleroderma. It was a relief to work with such a seasoned professional. My daughter loved her -- which was good because we saw her frequently. Dr. Wallace was aggressive in her treatment but that was always carefully weighed by what was best for my child and what would allow her to lead a normal life. We saw Dr. Wallace from 1999-2005. By then her scleroderma was in remission. My daughter is now married with two children. Dr. Wallace, thank you for all you did for Marie and for our family. God bless you.

    • Sean WA 01.05.12

      Dr. Wallace is my standard for judging my relationship with other doctors. Her knowledge, patients, and demeanor show that she is passionate not only about the information, but her patients as well. I feel well informed and that we couldn't be in better hands.

  • Award Name Award Description Awarded By Award Date
    SEATTLE MAGAZINE TOP DOCTOR - 2015 Seattle Magazine 2015
    SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
    Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
  • Presentations Title Event Location Date
    Disease Suppression without Steroids in Systemic JIA European League Against Rheumatism Congress Copenhagen, Denmark Jan. 1, 2009
    Pediatric Rheumatology Perspective FDA Public Workshop: Developing a Consolidated Pediatric Rheumatology Observational Registry Bethesda, MD Jan. 1, 2009
    Biologic Therapies for Juvenile Idiopathic Arthritis Rheumatology Grand Rounds, Hospital for Special Surgery NYC, New York Jan. 1, 2009
    CARRA and PRCSG – Distinct Roles, Issues in Pediatric Clinical Trials Consortia ACR Innovative Therapies in Autoimmune Diseases Conference Washington DC Jan. 1, 2009
  • Grant Title Grantor Amount Award Date
    TREAT Follow-up Study Amgen $338,125.00 Nov. 7, 2009
    Dynamics of Therapeutic Response within the TREAT trial NIH-NIAMS $15,284.00 Sept. 1, 2009
    Trial of Early Aggressive Therapy of Juvenile Idiopathic Arthritis (TREAT) NIH- NIAMS $193,417.00 Sept. 1, 2009
    Comparative Effectiveness Research in Pediatric Rheumatic Diseases: Leveraging CARRA for Improved Child Health NIH-NIAMS $994,839.00 Sept. 1, 2009
    Dynamic Assessment in Multicenter Trials – Supplement to Expand Testing of Pediatrics PROMIS Tool NIH $15,000.00 May 1, 2009
    STRIVE- Long term, multi-center, longitudinal post-marketing, observational registry of Humira in children with active Juvenile Idiopathic Arthritis. Per patient enrolled payments Abbott $per patient enrollment May 1, 2009
    Randomized Placebo Phase study of Rilonacept in the Treatment of systemic juvenile idiopathic arthritis NIH-NIAMS $Per patient enrolled payments July 1, 2008
    CARRA Enhanced Drug Safety Surveillance Study Pfizer $289,050.00 Oct. 1, 2007
    Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT) NIH – NIAMS $4,136,107.00 Sept. 1, 2006
    Private donation - To support research in Juvenile Rheumatoid Arthritis proceeds from endowment Private Jan. 1, 2004
    National Collaborative Study of Stem Cell Transplantation n/a $unfunded May 1, 1999
    CARRA- Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology NIH-NIAMS $09.01.09


Board Certification(s)

Pediatric Rheumatology

Medical/Professional School

University of Michigan Medical School, Ann Arbor


Pediatrics, University of Washington School of Medicine, Seattle


Reproductive Endocrinology, University of Washington School of Medicine, Seattle
Pediatric Rheumatology, University of Washington School of Medicine, Seattle

Research Focus Area

Translational Research, Aggressive Treatment of Juvenile Idiopathic Arthritis